These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 21681735

  • 1. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
    McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA.
    Cancer; 2011 Dec 15; 117(24):5461-8. PubMed ID: 21681735
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B.
    Cancer; 2012 Apr 15; 118(8):1982-8. PubMed ID: 21887681
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA, Morris PG, Cowell EP, Patil S, Hudis CA, McArthur HL.
    Clin Breast Cancer; 2016 Dec 15; 16(6):487-493. PubMed ID: 27622751
    [Abstract] [Full Text] [Related]

  • 4. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A, Smith I.
    Breast; 2011 Oct 15; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [Abstract] [Full Text] [Related]

  • 5. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
    Fehrenbacher L, Capra AM, Quesenberry CP, Fulton R, Shiraz P, Habel LA.
    J Clin Oncol; 2014 Jul 10; 32(20):2151-8. PubMed ID: 24888815
    [Abstract] [Full Text] [Related]

  • 6. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
    Chan A, McGregor SR.
    Intern Med J; 2012 Mar 10; 42(3):267-74. PubMed ID: 21241440
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J, Perez EA, Pienkowski T, Bell R.
    Oncologist; 2006 Mar 10; 11 Suppl 1():4-12. PubMed ID: 16971734
    [Abstract] [Full Text] [Related]

  • 8. Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?
    Tognela A, Beith J, Kiely B, Bastick P, Lynch J, Descallar J, Mok K.
    Clin Breast Cancer; 2015 Aug 10; 15(4):277-84. PubMed ID: 25676930
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study.
    Olszewski AJ, Migdady Y, Boolbol SK, Klein P, Boachie-Adjei K, Sakr BJ, Sikov W, Shao T.
    Breast Cancer Res Treat; 2013 Feb 10; 138(1):215-23. PubMed ID: 23354365
    [Abstract] [Full Text] [Related]

  • 12. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet Oncol; 2011 Mar 10; 12(3):236-44. PubMed ID: 21354370
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators.
    N Engl J Med; 2006 Feb 23; 354(8):809-20. PubMed ID: 16495393
    [Abstract] [Full Text] [Related]

  • 14. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
    Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K.
    J Clin Oncol; 2008 Dec 10; 26(35):5697-704. PubMed ID: 19001334
    [Abstract] [Full Text] [Related]

  • 15. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
    Bonifazi M, Franchi M, Rossi M, Zambelli A, Moja L, Zambon A, Corrao G, La Vecchia C, Zocchetti C, Negri E.
    Breast; 2014 Oct 10; 23(5):573-8. PubMed ID: 24934637
    [Abstract] [Full Text] [Related]

  • 16. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ, Truong PT, Sadek BT, Alexander CS, Wiksyk B, Shenouda M, Raad RA, Taghian AG.
    Ann Surg Oncol; 2014 Oct 10; 21(11):3490-6. PubMed ID: 24841346
    [Abstract] [Full Text] [Related]

  • 17. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
    de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.
    Breast Cancer Res Treat; 2017 Apr 10; 162(2):307-316. PubMed ID: 28155054
    [Abstract] [Full Text] [Related]

  • 18. Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.
    Araki K, Saji S, Gallas M, Pegram M, Sasaki Y.
    Breast Cancer; 2012 Apr 10; 19(2):95-103. PubMed ID: 21863310
    [Abstract] [Full Text] [Related]

  • 19. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM.
    J Clin Oncol; 2007 Feb 20; 25(6):634-41. PubMed ID: 17308268
    [Abstract] [Full Text] [Related]

  • 20. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D, Burris H, Peacock N, Raefsky E, Melnik M, Inhorn R, Shipley D, Hainsworth J.
    Breast Cancer Res Treat; 2010 Sep 20; 123(2):471-5. PubMed ID: 20658263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.